Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2025-08-21 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
第四届监事会第四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting held on August 20, 2025, where the Supervisory Board reviewed and approved the 2025 semi-annual report and related matters. The document includes voting results and references to the actual semi-annual report and other related reports published separately on the Beijing Stock Exchange website. The document itself does not contain the full semi-annual report or detailed financial statements but rather the Supervisory Board's approval and opinions on the report. The document length is short (2281 characters) and serves as a formal announcement of the Supervisory Board's resolutions rather than the report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement related to regulatory compliance and internal governance but does not contain the full interim report or detailed financial data required for an Interim/Quarterly Report (IR).
2025-08-21 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled "关联交易管理制度" which translates to "Related Party Transaction Management System". It is a detailed internal policy document outlining the principles, definitions, procedures, and governance related to related party transactions within the company. It includes sections on the scope, definitions of related parties, principles of related party transactions, approval procedures, disclosure requirements, and responsibilities. The document is issued and approved by the company's board and is dated August 22, 2025. There is no indication that this is a financial report, earnings release, or regulatory filing announcement. It is not a report publication announcement since it contains substantive content rather than a brief notice. It is not a management change announcement or voting results. The document is a governance-related internal policy document detailing the company's internal rules and governance practices regarding related party transactions. Therefore, the most appropriate classification is Governance Information (CGR).
2025-08-21 Chinese
董事、高级管理人员薪酬管理制度
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理制度' which translates to 'Remuneration Management System for Directors and Senior Management'. It details the company's policies and procedures regarding the compensation of directors and senior management, including approval processes, salary standards, and adjustments. There is no financial data or report of results, but rather a governance-related policy document. This fits the definition of a Remuneration Information report (DEF 14A), which details compensation for top executives and directors. The document is relatively short (1852 characters) and is not an announcement of a report but the policy itself. Therefore, the correct classification is DEF 14A with high confidence.
2025-08-21 Chinese
董事会秘书工作制度
Governance Information Classification · 95% confidence The document is titled '董事会秘书工作制度' which translates to 'Board Secretary Work System'. It details the rules, responsibilities, appointment, and dismissal procedures for the company's board secretary. It references company governance, legal compliance, and internal management practices. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, and no earnings information. The document is a governance-related internal policy document approved by the board. It is not a report, announcement of voting results, or any financial filing. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-08-21 Chinese
董事会战略与可持续发展委员会工作细则
Governance Information Classification · 95% confidence The document is titled as the 'Board of Directors Strategic and Sustainable Development Committee Working Rules' of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the composition, responsibilities, meeting rules, and procedures of a board committee. There is no financial data, no mention of financial results, no shareholder voting results, no executive changes, no legal proceedings, no capital changes, and no report publication announcements. The document is a governance-related internal regulation about the board committee's operation and duties. Therefore, it fits best under Governance Information (CGR). The document length is 3099 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Hence, the classification is CGR with high confidence.
2025-08-21 Chinese
承诺管理制度
Governance Information Classification · 95% confidence The document is titled '承诺管理制度' (Commitment Management System) issued by Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the company's internal policy regarding commitments made by the company, its controlling shareholders, directors, and other related parties. The document includes procedural rules about the making, disclosure, fulfillment, modification, and legal responsibilities of such commitments. It references company law, securities law, and stock exchange listing rules, and mentions board and shareholder meeting approvals. The document is a governance-related policy or internal regulation rather than a financial report, earnings release, or announcement of voting results. It is not a report of financial performance or audit, nor is it a call transcript or capital update. It is a governance document outlining internal rules and procedures. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 2376 characters, which is relatively short but contains substantive governance content, not just an announcement or notice. Hence, it is not RPA or RNS.
2025-08-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.